BAY 58-2667: Clinical Trials

4 terminated. 4 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	4	Terminated 4

Follow BAY 58-2667: new trials by email Literature Review of BAY 58-2667 trials Research Report on BAY 58-2667

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF) Cinaciguat (BAY58-2667), Placebo - Heart Failure, Heart Decompensation	Phase 2	Terminated	Bayer	62	2010-04-01	2015-10-08
BAY58-2667 Dose Finding Trial Investigating Fixed Doses in Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF) Cinaciguat (BAY58-2667), Placebo - Acute Heart Failure	Phase 2	Terminated	Bayer	12	2010-03-01	2015-10-08
A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF) Cinaciguat (BAY58-2667), Placebo - Acute Heart Failure	Phase 2	Terminated	Bayer	5	2010-03-01	2015-10-08
Placebo Controlled, Randomized, Double-blind, Multi-center Study to Investigate the Efficacy and Tolerability of BAY58-2667 Placebo, Cinaciguat (BAY58-2667) - Congestive Heart Failure	Phase 2	Terminated	Bayer	150	2007-12-01	2017-04-18

Conditions studied

Heart Failure (4)

Sponsors

Bayer (4)

Countries

Germany (4)  ·  United States (4)  ·  Israel (3)  ·  Italy (3)  ·  Poland (3)  ·  Austria (2)  ·  Canada (2)  ·  Croatia (2)  ·  Czechia (2)  ·  Finland (2)  ·  France (2)  ·  Hungary (2)  ·  Ireland (2)  ·  Japan (2)  ·  Russia (2)

Results publications

PMID 22713287, PMID 22778174

NIH funding

2009 (3)